Overview

KP415 Classroom Study in Children (6-12 Years of Age) With ADHD

Status:
Completed
Trial end date:
2018-05-16
Target enrollment:
Participant gender:
Summary
The study is a multicenter, dose-optimized, double-blind, randomized, placebo-controlled, parallel efficacy laboratory classroom study with KP415 in children with Attention-Deficit/Hyperactivity Disorder (ADHD).
Phase:
Phase 3
Details
Lead Sponsor:
KemPharm, Inc.